AMAG CMO hits the exit just as biotech searches for new CEO to right a ship rocked by Makena controversy
Heading into 2020, AMAG Pharmaceuticals has sketched big plans to salvage its wobbly operations — battling a revenue squeeze and a critical FDA review of its preterm birth drug — under a new CEO. Today, it announced that the chief medical officer won’t be staying, either.
Julie Krop, who joined AMAG in 2015, will decamp by the end of the month, leaving a void in the biotech’s development group just as it pledges to persuade the FDA to keep Makena on the market and advance a “potentially exciting pipeline.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.